Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions Group Plc LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 0.59% 255.00 254.00 255.00 257.00 240.50 243.00 1,002,843 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 86.8 10.1 4.0 63.9 549

Advanced Medical Solutions Share Discussion Threads

Showing 7001 to 7024 of 7375 messages
Chat Pages: Latest  283  282  281  280  279  278  277  276  275  274  273  272  Older
DateSubjectAuthorDiscuss
06/2/2018
12:48
Whoops! Didn't see that coming.
wetdream
05/2/2018
16:51
Hopefully support at 300p.
wetdream
05/2/2018
16:22
Surprised me too. Bought another 1000 though!
joshgroeny
05/2/2018
15:41
Any idea why the market picked on AMS today down 5% on small volume.
dealit
18/1/2018
16:13
Next leg up?
volsung
16/1/2018
11:10
Easy to forget it was 200p at the start of 2017!
wetdream
16/1/2018
11:08
Seemed to be a series of five-figure 'O' trade sells yesterday that took the share price down below 300p. Normal service resumed today however. ;-)
wetdream
10/1/2018
20:52
Could be a Head and shoulders pattern. Target price is around historical support 295-298. Potential turn date 26/01/2018.
bamboo2
10/1/2018
19:05
£3.10 was resistance but now support imho.
wetdream
10/1/2018
12:33
Time for a top up on this overlooked stock.
volsung
14/12/2017
10:46
Pre-Close Trading Update Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces an update on trading for the year ending 31 December 2017. The Group continues to make good progress and the Board expects revenue and profitability to be in line with current market expectations that include the positive impact from the recent Organogenesis licensing deal. Chris Meredith, Chief Executive Officer of AMS, said: "The Group continues to deliver strong organic growth supported by our Research and Development activities that provide both product innovation and intellectual property. AMS is well positioned to continue on its growth trajectory." The Group expects to publish its Preliminary Results for the year to 31 December 2017 in March 2018. Adoption of IFRS 15 IFRS 15 (Revenue from Contracts with Customers) becomes mandatory for AMS from 1 January 2018. The main effect for AMS will be to recognise the fees received from royalty payments and from regulatory agreements as Revenue rather than as Other Income. It will have no impact on profit or cash flow. The Group however has chosen to adopt IFRS 15 early and will be reporting its results for 2017 in line with its requirements. -End -
grabster
04/12/2017
09:54
ams,should find a use for nanene- see VRS
p@
20/11/2017
09:44
Could be the start of the next leg up. I've bought a few this am on that hunch
volsung
14/11/2017
13:15
No buyers in sight so share price drops on pitiful volume.
wetdream
10/11/2017
10:35
Markets very nervous imho.
wetdream
05/11/2017
10:41
Next trading update should be mid December.
potty punter
30/10/2017
15:09
Yes indeed `malcontent` highest ever share price today. Where to now, are we a target for the big boys?
dealit
30/10/2017
14:09
this one is out of the traps again and at a gallop what a stock
malcontent
27/10/2017
12:09
SP holding up well, given volume of sells-and it's a Friday.....
wetdream
27/10/2017
12:00
http://www.organogenesis.com/news/press-announcements.html
mirandaj
26/10/2017
23:51
Cgequityinvest, Couldn't agree more. It's the US link up that's more important (ok, the money's important too, but AMS is pretty cash-rich already). Traditionally, US cos will do their best to link up with other US cos first. It's a feather in AMS's cap that they've made this move.
wetdream
26/10/2017
17:34
Ok, thanks cge, makes sense..
ilovefrogs
26/10/2017
17:04
I think the upside comes from :- * the income is a royalty stream so it should fall largely through to the bottom line. i.e. i would expect the margin to be very high. Based on brokers expectations of £18.1m net profit for y/e Dec, the payment of $2.5m (say £1.9m equiv) could increase eps by nearly 10% (assuming minimal costs to be offset). This equates closely with the circa 9% price increase today. * strategically its another key step in the US and will help further establish their presence over there. The US company looks a bit small to be a potential purchaser of AMS - its not publically quoted at present. will be interesting to see what revised forecasts emerge from the brokers over the next week or so. Still at a high p/e multiple but this is a quality business with a long, strong track record of growth and cash generation.
cgequityinvest
26/10/2017
15:13
Anyone know just how significant the RNS is. Doesn't give any indications of revenue above agreed minimums (which are small in the scheme of things)
ilovefrogs
Chat Pages: Latest  283  282  281  280  279  278  277  276  275  274  273  272  Older
ADVFN Advertorial
Your Recent History
LSE
AMS
Advanced M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210414 01:13:13